Effects of myricetin on the bioavailability of carvedilol in rats

Pharmaceutical Biology

Volumn 50, Issue 4, 2012, Pages 516-522

  Lee, W ^a   Woo, E R ^a   Choi, J S ^a  

^a Chosun University   (South Korea)

Author keywords

Bioavailability; Carvedilol; CYP2C9; CYP2D6; Myricetin; P gp; Rats

Indexed keywords

CARVEDILOL; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; GLYCOPROTEIN P; MYRICETIN; RHODAMINE 123;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME INHIBITION; HERB DRUG INTERACTION; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CARBAZOLES; CELL LINE, TUMOR; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; FLAVONOIDS; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINE, SMALL; LIVER; MALE; P-GLYCOPROTEIN; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123;

RATTUS;

EID: 84863290976     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2011.611141     Document Type: Article

References (31)

1. Abshagen U. (1987). A new molecule with vasodilating and beta-adrenoceptor blocking properties. J Cardiovasc Pharmacol, 10 Suppl 11, S23-S32.
2. Bart J, Dijkers EC, Wegman TD, de Vries EG, van der Graaf WT, Groen HJ, Vaalburg W, Willemsen AT, Hendrikse NH. (2005). New positron emission tomography tracer (11)Ccarvedilol reveals P-glycoprotein modulation kinetics. Br J Pharmacol, 145, 1045-1051. (Pubitemid 43079976)
3. Benet LZ, Cummins CL, Wu CY. (2003). Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab, 4, 393-398. (Pubitemid 37279364)
4. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res, 23, 1675-1686. (Pubitemid 44200529)
5. Cournot A, Lim C, Duchier J, Safar M. (1992). Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J Cardiovasc Pharmacol, 19 Suppl 1, S35-S39.
6. Crespi CL, Miller VP, Penman BW. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem, 248, 188-190. (Pubitemid 27218241)
7. Cummins CL, Jacobsen W, Benet LZ. (2002). Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ter, 300, 1036-1045. (Pubitemid 34165010)
8. DasGupta P, Broadhurst P, Lahiri A. (1991). The effects of intravenous carvedilol, a new multiple action vasodilatory beta-blocker, in con gestive heart failure. J Cardiovasc Pharmacol, 18 Suppl 4, S12-S16.
9. Dixon RA, Steele CL. (1999). Flavonoids and isofavonoids-a gold mine for metabolic engineering. Trends Plant Sci, 4, 394-400. Frishman WH. (1998). Carvedilol. N Engl J Med, 339, 1759-1765.
10. Häkkinen SH, Kärenlampi SO, Heinonen IM, Mykkänen HM, Törrönen AR. (1999). Content of the favonols quercetin, myricetin, and kaempferol in 25 edible berries. J Agric Food Chem, 47, 2274-2279. (Pubitemid 29325110)
11. Hampton JR. (1996). Beta-blockers in heart failure-the evidence from clinical trials. Eur Heart J, 17 Suppl B, 17-20. (Pubitemid 26136855)
12. Han CY, Cho KB, Choi HS, Han HK, Kang KW. (2008). Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis, 29, 1837-1844.
13. Kaminsky LS, Fasco MJ. (1991). Small intestinal cytochromes P450. Crit Rev Toxicol, 21, 407-422.
14. Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G. (2005). Structure-activity relationships of the inhibitory effects of favonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull, 28, 2274-2278. (Pubitemid 41757420)
15. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. (1992). Identifcation of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest, 90, 1871-1878.
16. Lewis DFV. (1996). Cytochromes P450: Structure, Function and Mechanism. Bristol, England, Taylor & Francis Publisher and Distributor.
17. Lund-Johansen P, Omvik P, Nordrehaug JE, White W. (1992). Carvedilol in hypertension: Effects on hemodynamics and 24-hour blood pressure. J Cardiovasc Pharmacol, 19 Suppl 1, S27-S34.
18. McTavish D, Campoli-Richards D, Sorkin EM. (1993). Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efcacy. Drugs, 45, 232-258. (Pubitemid 23092628)
19. Morgan T. (1994). Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet, 26, 335-346. (Pubitemid 24148199)
20. Neugebauer G, Akpan W, von Möllendorf E, Neubert P, Reif K. (1987). Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol, 10 Suppl 11, S85-S88.
21. Neugebauer G, Neubert P. (1991). Metabolism of carvedilol in man. Eur J Drug Metab Pharmacokinet, 16, 257-260.
22. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. (2001). Flavonoids: A review of probable mechanisms of action and potential applications. Am J Clin Nutr, 74, 418-425. (Pubitemid 32880250)
23. Nishijima CM, Rodrigues CM, Silva MA, Lopes-Ferreira M, Vilegas W, Hiruma-Lima CA. (2009). Anti-hemorrhagic activity of four Brazilian vegetable species against Bothrops jararaca venom. Molecules, 14, 1072-1080.
24. Oldham HG, Clarke SE. (1997). In vitro identifcation of the human cytochrome P450 enzymes involved in the metabolism of R(+)-and S(-)-carvedilol. Drug Metab Dispos, 25, 970-977. (Pubitemid 27357695)
25. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. (1993). P-Glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett, 324, 99-102. (Pubitemid 23165045)
26. Tiwari R, Mohan M, Kasture S, Maxia A, Ballero M. (2009). Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats. Phytother Res, 23, 1361-1366.
27. Václavíková R, Horský S, Simek P, Gut I. (2003). Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxi-dants. Naunyn Schmiedebergs Arch Pharmacol, 368, 200-209. (Pubitemid 37255481)
28. von Möllendorf E, Abshagen U, Akpan W, Neugebauer G, Schröter E. (1986). Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ter, 39, 677-682.
29. von Moltke LL, Weemhof JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. (2004). Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol, 56, 1039-1044. (Pubitemid 39140060)
30. Xue B, Li J, Chai Q, Liu Z, Chen L. (2008). Effect of total favonoid fraction of Astragalus complanatus R. Brown on angiotensin II-induced portal-vein contraction in hypertensive rats. Phytomedicine, 15, 759-762.
31. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. (2007). Quantifcation of carvedilol in human plasma by liquid chromatography using fuorescence detection: Application in pharmacokinetic studies. J Pharm Biomed Anal, 44, 250-253. (Pubitemid 46551580)